Get the Stockscreener App
1.95
0.51%
-0.01
After Hours:
1.93
-0.02
-1.03%
Lexicon Pharmaceuticals Inc stock is traded at $1.95, with a volume of 1.85M.
It is down -0.51% in the last 24 hours and down -12.56% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.96
Open:
$1.95
24h Volume:
1.85M
Relative Volume:
0.76
Market Cap:
$866.18M
Revenue:
$69.64M
Net Income/Loss:
$-26.09M
P/E Ratio:
-27.27
EPS:
-0.0715
Net Cash Flow:
$-38.80M
1W Performance:
+3.72%
1M Performance:
-12.56%
6M Performance:
+62.50%
1Y Performance:
+191.04%
1-Day Range:
$1.92
$2.025
1-Week Range:
$1.84
$2.025
52-Week Range:
$0.6547
$2.53
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.95 | 870.62M | 69.64M | -26.09M | -38.80M | -0.0715 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals (LXRX) reports break-even earnings for Q1 - MSN
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? - Insider Monkey
Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global DrugmakerNews and Statistics - IndexBox
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? - Yahoo Finance
LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into common stock holdings - Stock Titan
Diane E. Sullivan converts 89,312 RSUs at Lexicon Pharmaceuticals (LXRX) - Stock Titan
[Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Lexicon Pharmaceuticals (LXRX) director exercises 89,312 RSUs into shares - Stock Titan
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into 213,771-share stake - Stock Titan
Lexicon (NASDAQ: LXRX) director converts 89,312 restricted stock units into common stock - Stock Titan
Lexicon (NASDAQ: LXRX) director converts 89,312 RSUs into common stock, boosts stake - Stock Titan
LXRX: Pivotal HCM trial nears completion as pipeline and partnerships drive transformation - TradingView
How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates - Yahoo Finance
New Type 1 diabetes drug data from Lexicon at ADA 2026 meeting - Stock Titan
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions - The Manila Times
LXRX Stock Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Lexicon (LXRX) Q1 2026 Earnings Transcript - The Globe and Mail
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Lexicon Pharma schedules Jefferies healthcare fireside chat for June 4 - Stock Titan
SA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRX - Seeking Alpha
Lexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade) (NASDAQ:LXRX) - Seeking Alpha
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
LXRX Stock Price, Quote & Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
5 Best Penny Stocks to Buy for Long Term - Insider Monkey
Lexicon anticipates SONATA-HCM enrollment completion by mid-2026 while highlighting $100m Hercules debt facility - MSN
A Look At Lexicon Pharmaceuticals (LXRX) Valuation After Improved Q1 Revenue And Narrowed Net Loss - Sahm
Lexicon Pharmaceuticals: up to 50 percent of type 2 diabetes patients affected by painful neuropathy - Traders Union
Lexicon Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-05-15 - Seeking Alpha
Navigating Life with Hypertrophic Cardiomyopathy - GlobeNewswire Inc.
Lexicon Pharmaceuticals (LXRX) Is Up 52.5% After Q1 Loss Narrows And Revenue JumpsHas The Bull Case Changed? - simplywall.st
Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's Changed - Yahoo Finance
Lexicon Pharmaceuticals management to join Nasdaq HQ fireside chat - Traders Union
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - Herald and News
Fireside chat at Nasdaq HQ: Lexicon joins H.C. Wainwright investor event May 19 - Stock Titan
LXRX Maintained by Citigroup -- Price Target Raised to $3.10 - GuruFocus
$Lexicon Pharmaceuticals (LXRX.US)$ 🚀🚀🚀🚀🚀🤩🤩🤩🤩🤩 - Moomoo
Citigroup Issues Positive Forecast for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price - MarketBeat
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $3.1 - Moomoo
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones - Yahoo Finance
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexicon Pharmaceuticals Inc Stock (LXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
126,122 |
| SOBECKI CHRISTOPHER J | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
293,177 |
| Cheung Ivan | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
89,312 |
| BARKER SAM L | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
213,771 |
| Amouyal Philippe | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
374,486 |
| DEBBANE RAYMOND | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
1,995,498 |
| Artal Participations S.a r.l. | Director |
Apr 30 '26 |
Option Exercise |
0.00 |
20,421,735 |
0 |
175,156,062 |
| DEBBANE RAYMOND | Director |
Feb 25 '26 |
Buy |
1.49 |
2,000 |
2,980 |
1,906,186 |
| DEBBANE RAYMOND | Director |
Feb 23 '26 |
Buy |
1.47 |
100,000 |
147,000 |
1,904,186 |
| DEBBANE RAYMOND | Director |
Feb 20 '26 |
Buy |
1.48 |
100,000 |
147,790 |
1,804,186 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):